期刊文献+

铜绿假单胞菌对碳青霉烯耐药机制的研究 被引量:9

Study on mechanism of carbapemem-resistant Pseudomonas aeruginosa
原文传递
导出
摘要 铜绿假单胞菌(Pseudomonas aeruginosa,PA)是一种常见的院内获得性感染的条件致病菌,其所致感染可供选择的有效抗菌药物甚少。碳青霉烯类抗生素常被作为治疗对其它β-内酰胺抗生素耐药的革兰阴性菌的最后一道防线,但是近年来PA对其耐药率在逐年上升。PA对碳青霉烯的耐药机制是复杂的,通常是多种机制综合作用产生的,目前认为主要是由于:产生β-内酰胺酶(碳青霉烯酶、AmpC酶)、外膜通透性改变和主动外排泵系统的存在。 Pseudomonas aeruginosa(PA) is an important conditional pathogen in the hospital infection. Carhapenems is used to he the last resort against infections caused by PA resistant to other β-lactams. But in recent years PA has acquired a great resistance and multiple resistance by many ways. The resistant mechanism of carbapenem-resistant PA is complicated, but the main mechanism includes β-lactamases(Carbapenemase, AmpC enzyme), change of the outermemhrane permeability and active efflux pump.
作者 吴迪 陈升汶
出处 《国际呼吸杂志》 2007年第8期610-612,共3页 International Journal of Respiration
关键词 铜绿假单胞菌 碳青霉烯 耐药机制 Pseudomonas aeruginosa Carbapemem Resistant mechanism
  • 相关文献

参考文献15

  • 1陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 2杨健,陈升汶,吴伟元,卢月梅,何林,朱克群.医院细菌耐药监测研究[J].中华医院感染学杂志,2003,13(4):363-365. 被引量:51
  • 3蒋晓飞,洪秀华,孙景勇,陈轶兰,倪语星.多重耐药铜绿假单胞菌超广谱β-内酰胺酶分析[J].中华微生物学和免疫学杂志,2002,22(4):443-446. 被引量:67
  • 4National Nosocomial Infections Surveillance (NNIS) System Report, available from: http:// www. cdc. gov/ ncidod/diseases/nnis/nnis0596.htm
  • 5欧阳金鸣,褚云卓,丁丽萍,邓宇欣.铜绿假单胞菌耐药性的临床调查[J].中国医科大学学报,2006,35(1):84-86. 被引量:15
  • 6Nordmann P, Poirel L. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect, 2002,8 : 321-331.
  • 7Bush K. Metallo-bet-lactamases: a class apart. Clin Infect Dis,1998,27:S48-S53.
  • 8Galleni M, Lamotte-Brasseur J, Rossolini GM, et al. Standard numbering scheme for class beta-lactamases. Antimicrob Agents Chemother, 2001,45:660-663.
  • 9Bush K, Jacoby GA, Mederios AA. A function classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother,1995,39:1211-1233.
  • 10Jacobs C, Frere JM, Normark S, et al. Cytosolic intermediates forcese wall biosynthesis and degradation comtroc inducible beta-lactamase resistance in Gram-negative bacteria. Cell, 1997,88:823-827.

二级参考文献26

  • 1周立新,张秀平,方滨,李轶男,誉铁鸥,毛克江,苏艳玲.重症监护病房感染患者铜绿假单胞菌的分离与耐药性分析[J].中华医院感染学杂志,2004,14(7):807-808. 被引量:61
  • 2Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 3Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 4Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 5Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 6National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
  • 7Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
  • 8National Committee for Clinical Laboratory Standards.Performance standards for antimicrobioal susceptibility testing:the fourteenth information supplement[S],M100 -S 14:NCCLS,2004,24 (1).
  • 9Lauretti L,Riccio ML,Mazzariol A,et al.Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate[].Antimicrobial Agents and Chemotherapy.1999
  • 10Rasmussen BA,Bush K.Carbapenem-hydrolyzingβ-lactamases[].Antimicrobial Agents and Chemotherapy.1997

共引文献632

同被引文献61

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部